BR112012009855A2 - métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit - Google Patents

métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit

Info

Publication number
BR112012009855A2
BR112012009855A2 BR112012009855A BR112012009855A BR112012009855A2 BR 112012009855 A2 BR112012009855 A2 BR 112012009855A2 BR 112012009855 A BR112012009855 A BR 112012009855A BR 112012009855 A BR112012009855 A BR 112012009855A BR 112012009855 A2 BR112012009855 A2 BR 112012009855A2
Authority
BR
Brazil
Prior art keywords
drug
determining
level
optimizing
kit
Prior art date
Application number
BR112012009855A
Other languages
English (en)
Inventor
Ohrmund Linda
Singh Sharat
Long Wang Shui
Original Assignee
Prometheus Laboratoires Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Laboratoires Inc filed Critical Prometheus Laboratoires Inc
Publication of BR112012009855A2 publication Critical patent/BR112012009855A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir a toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um anticorpo para uma droga, e, kit. a presente invenção fornece ensaios para detectar e medir a presença ou nível de produtos terapêuticos de drogas e autoanticorpos anti-tnfa em uma amostra. a presente invenção é útil para otimizar a terapia e monitorar pacientes que recebem os produtos terapêuticos de drogas anti tnfa, para detectar a presença ou nível de autoanticorpos (por exemplo, haca e/ou haha) contra a droga.
BR112012009855A 2009-10-26 2010-10-26 métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit BR112012009855A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25504809P 2009-10-26 2009-10-26
US26287709P 2009-11-19 2009-11-19
US32463510P 2010-04-15 2010-04-15
US34556710P 2010-05-17 2010-05-17
US35126910P 2010-06-03 2010-06-03
US38967210P 2010-10-04 2010-10-04
US39358110P 2010-10-15 2010-10-15
PCT/US2010/054125 WO2011056590A1 (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Publications (1)

Publication Number Publication Date
BR112012009855A2 true BR112012009855A2 (pt) 2018-06-26

Family

ID=43618083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009855A BR112012009855A2 (pt) 2009-10-26 2010-10-26 métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit

Country Status (15)

Country Link
US (5) US8574855B2 (pt)
EP (1) EP2494352B1 (pt)
JP (3) JP5697677B2 (pt)
KR (2) KR101881714B1 (pt)
CN (2) CN102695955B (pt)
AU (4) AU2010315547C1 (pt)
BR (1) BR112012009855A2 (pt)
CA (2) CA3108458A1 (pt)
ES (1) ES2796530T3 (pt)
IL (2) IL219315B (pt)
MX (2) MX2012004877A (pt)
NZ (3) NZ621655A (pt)
RU (2) RU2571489C2 (pt)
WO (1) WO2011056590A1 (pt)
ZA (2) ZA201203717B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558303T3 (es) 2002-09-11 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) * 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
CN110544517A (zh) 2011-05-10 2019-12-06 雀巢产品有限公司 用于个体化治疗管理的疾病活动性表征方法
CN103782172A (zh) * 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
EP2786156A2 (en) * 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
JP6272788B2 (ja) 2012-03-08 2018-01-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 循環中の免疫複合体を特徴付けるためのマルチプレックス式クロマトグラフィー−イムノアッセイ法
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US10132736B2 (en) * 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
CA2887035A1 (en) 2012-10-05 2014-04-10 Nestec S.A. Methods for predicting and monitoring mucosal healing
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
CN110988081A (zh) * 2013-05-16 2020-04-10 比勒陀利亚大学 诊断结核病的方法
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
EP3077818B1 (en) 2013-12-03 2020-02-05 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
EP3210016A1 (en) 2014-10-20 2017-08-30 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
WO2016063223A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
EP3227685A1 (en) 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
CA2969609C (en) * 2014-12-05 2023-02-28 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
CN107110853A (zh) * 2015-01-09 2017-08-29 阿通诺米斯公司 确定TNFα抑制药及其相应抗药抗体的量的通用测定法
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
ES2716900T3 (es) * 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
EP3165922B1 (en) 2015-11-06 2020-06-17 Promise Proteomics A method for quantifying therapeutic antibodies
WO2017201142A1 (en) * 2016-05-17 2017-11-23 Memorial Sloan Kettering Cancer Center Treatment of lung adenocarcinoma
CN109791142B (zh) * 2016-07-08 2022-11-29 W 健康公司 用于确定样品中治疗性单克隆抗体及其相应抗药物抗体的量的通用测定
SG11202003216QA (en) 2017-10-10 2020-05-28 Prometheus Biosciences Inc Methods for monitoring vedolizumab treatment
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
CN112313511A (zh) * 2018-04-20 2021-02-02 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法中的色谱柱鉴定
US20230035363A1 (en) * 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
ES2150970T3 (es) 1993-09-07 2000-12-16 Wako Pure Chem Ind Ltd Procedimiento y reactivo para la medida de la actividad del complemento.
JPH07110331A (ja) * 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
RU2270030C2 (ru) * 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
JP3718435B2 (ja) * 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
EP0882984B1 (en) 1996-08-12 2010-10-06 Sekisui Kagaku Kogyo Kabushiki Kaisha Containers and kits for the determination of cell functions, and method for the determination thereof
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2348698C (en) * 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
DE19858777B4 (de) * 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
PL356049A1 (en) * 1999-12-06 2004-06-14 Leo Pharma A/S Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
AU2262501A (en) 1999-12-16 2001-06-25 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1370867B1 (en) 2001-03-02 2010-08-04 Activx Biosciences, Inc. Protein profiling platform
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
US7524502B2 (en) 2001-11-12 2009-04-28 Merck Patent Gmbh Modified anti-TNF alpha antibody
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
BR0313151A (pt) 2002-08-01 2007-07-17 Wyeth Corp métodos e reagentes que se relacionam à inflamação e à apoptose
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
CN100509847C (zh) * 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
BRPI0413575A (pt) 2003-08-14 2006-10-17 Wyeth Corp anticorpos anti-idiotìpicos anti-lewis y e seus usos
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
EP1769244A4 (en) 2004-06-30 2008-05-14 Dow Kenneth Centocor Inc DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
JP2008545958A (ja) 2005-05-20 2008-12-18 ジェネンテック・インコーポレーテッド 自己免疫性疾患の被検体の生体試料の前処理
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
ES2530265T3 (es) 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
WO2007037910A2 (en) 2005-09-14 2007-04-05 Fred Hutchinson Cancer Research Center Specific removal of activated immune cells
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
JP2009514977A (ja) * 2005-11-08 2009-04-09 メダレックス インコーポレーティッド 免疫刺激性治療用抗体による治療に付随した腸炎に対するＴＮＦ−α遮断剤処置法
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
US20080286774A1 (en) 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
CA2712021A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
CA2716522A1 (en) 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
CA2969609C (en) 2014-12-05 2023-02-28 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

Also Published As

Publication number Publication date
ZA201203717B (en) 2018-11-28
IL219315B (en) 2018-01-31
AU2015202899B2 (en) 2017-06-01
JP5697677B2 (ja) 2015-04-08
JP2015148616A (ja) 2015-08-20
US20140057367A1 (en) 2014-02-27
KR20170088437A (ko) 2017-08-01
CA2778454A1 (en) 2011-05-12
AU2019205009A1 (en) 2019-08-01
IL219315A0 (en) 2012-06-28
RU2012121710A (ru) 2013-12-10
MX2012004877A (es) 2012-05-23
JP5878253B2 (ja) 2016-03-08
US20200018751A1 (en) 2020-01-16
MX343328B (es) 2016-11-01
US8865417B2 (en) 2014-10-21
KR101761541B1 (ko) 2017-07-26
RU2571489C2 (ru) 2015-12-20
WO2011056590A1 (en) 2011-05-12
AU2010315547B2 (en) 2015-03-05
IL256728A (en) 2018-04-09
KR101881714B1 (ko) 2018-07-24
ES2796530T3 (es) 2020-11-27
CN102695955B (zh) 2015-03-18
CN104634955A (zh) 2015-05-20
EP2494352A1 (en) 2012-09-05
EP2494352B1 (en) 2020-04-08
US10386366B2 (en) 2019-08-20
KR20120108978A (ko) 2012-10-05
CN104634955B (zh) 2016-09-14
US8574855B2 (en) 2013-11-05
NZ599456A (en) 2014-06-27
CN102695955A (zh) 2012-09-26
JP2016106222A (ja) 2016-06-16
RU2015148676A (ru) 2019-01-15
AU2015202899A1 (en) 2015-06-18
CA3108458A1 (en) 2011-05-12
CA2778454C (en) 2021-03-02
AU2010315547A1 (en) 2012-05-10
AU2010315547C1 (en) 2015-06-04
JP2013508739A (ja) 2013-03-07
ZA201504548B (en) 2019-10-30
AU2017213584B2 (en) 2019-04-18
US9506920B2 (en) 2016-11-29
JP6082831B2 (ja) 2017-02-15
US20150024404A1 (en) 2015-01-22
US20120329172A1 (en) 2012-12-27
RU2015148676A3 (pt) 2019-06-18
NZ706187A (en) 2016-09-30
AU2017213584A1 (en) 2017-08-31
NZ621655A (en) 2015-08-28
US20170184588A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
BR112012009855A2 (pt) métodos para determinar uma quantidade eficaz de uma droga, para otimizar a terapia e/ou reduzir as toxicidade a uma droga, para determinar a presença ou nível de uma droga, para otimizar a quantidade terapêutica de uma droga e para determinar a presença ou nível de um autoanticorpo para uma droga, e, kit
BR112013020981A2 (pt) ensaios para a detecção de auto-anticorpos para os fármacos anti-tnf<244>
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
EP4235181A3 (en) Biomarker detection process and assay of neurological condition
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
BR112014013082A2 (pt) método para detectar adutos nucleossomos
EA201170361A1 (ru) Ценный документ и способ определения степени загрязнения или изнашивания такого документа
TR201904386T4 (tr) Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem.
BR112013027867A2 (pt) "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
BRPI0820876B8 (pt) método para determinação da quantidade de estrona em uma amostra de fluido corporal
BR112015012482A2 (pt) ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
BR112016008956A2 (pt) Detecção de atividade de clivagem de uma enzima
MX2012009908A (es) Ensayos y equipos para la serotipificacion de pseudomas aeruginosa y secuencias de oligonucleotido utiles en dichos metodos y equipos.
BR112014012313A2 (pt) kit para a detecção de isoformas 1-11 de kpc beta-lactamases (blakpc1-11) e métodos para determinar a presença de patógeno resistente a carbapenema em amostra e de sequências de ácidos nucleicos que codificam as isoformas 1-11 de kpc beta-lactamases (blakpc1-11) ou fragmentos dos ácidos nucleicos que codificam as isoformas 1-11 de kpc beta-lactamases (blakpc1-11)
BR112014000219A2 (pt) dispositivo de ensaio para a detecção de uma enzima ativa em uma amostra, método de determinação de presença e dos níveis de uma enzima ativa em uma amostra, kit, dispositivo de ensaio, ou método de uso ou o uso do mesmo e uso
BRPI1009573A2 (pt) método para avaliar uma condição artrítica em um sujeito, kit para detectar a presença de um auto-anticorpo, e, método para determinar o subtipo de artrite em um paciente.
MY149500A (en) The quantitative determination of risedronate in urine by spe-lc-ms-ms
SG10201806729VA (en) Novel assay to detect human periostin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NESTEC S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]